RELITREXED 500MG INJ VIAL

About

RELITREXED 500MG INJ VIAL is an antifolate antineoplastic agent designed to inhibit multiple folate-dependent enzymes crucial for pyrimidine and purine synthesis, which are essential processes for cell replication. By disrupting these pathways, RELITREXED effectively halts the growth and division of cancer cells. It is primarily indicated for the treatment of various cancers, most notably non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. The drug's targeted mechanism of action helps in controlling tumor progression and improving patient outcomes. Administered intravenously, it requires careful patient selection and pre-medication with folic acid and vitamin B12 to mitigate certain side effects, ensuring optimal therapeutic benefit.

Uses

• Treatment of non-small cell lung cancer (NSCLC)
• Management of malignant pleural mesothelioma
• Advanced colorectal cancer (off-label use)
• Other solid tumors in specific protocols

Directions For Use

Administered intravenously by a healthcare professional. Pre-medication with folic acid and vitamin B12 is required.

Benefits

• Effective in NSCLC and mesothelioma
• Improves survival rates in indicated cancers
• Can be used as monotherapy or in combination
• Manageable side effect profile with appropriate supportive care
• Established treatment guidelines and protocols
• Targeted mechanism of action against cancer cell replication

Side Effects

• Myelosuppression (neutropenia, thrombocytopenia, anemia)
• Fatigue
• Nausea and vomiting
• Stomatitis (mouth sores)
• Diarrhea
• Rash
• Alopecia (hair loss)
• Renal dysfunction
• Peripheral edema
• Infection
• Fever
• Anorexia

Safety Measures

• Alcohol - Avoid alcohol due to potential for increased gastrointestinal irritation and liver toxicity.
• Pregnancy - Contraindicated; highly teratogenic. Use effective contraception during and after treatment.
• Breastfeeding - Contraindicated; drug may pass into breast milk and harm the infant.
• Liver - Use with caution; monitor liver function, though primary excretion is renal.
• Kidney - Dose adjustment is required in patients with renal impairment; monitor kidney function closely.
• Lung - Monitor for interstitial lung disease; rare but serious pulmonary toxicity can occur.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.